Endogenous Peptide
Somatostatin-14 and Somatostatin-28 Share a Precursor
Endogenous somatostatin is produced in more than one mature form and signals through a diverse receptor family. Precursor processing, local action, and measurement limits shape how the evidence should be read.
Educational content only. Not medical advice.
One precursor produces more than one mature form
The SST gene encodes preprosomatostatin, which enters the secretory pathway and is processed into somatostatin-14 and the longer somatostatin-28, among related intermediates. Both mature peptides include a disulfide-linked cyclic region. Tissue-specific processing changes their relative abundance. A result labeled somatostatin should specify which molecular forms the assay or experiment can distinguish.
Somatostatin acts as a local and endocrine regulator
Somatostatin-producing cells occur in the hypothalamus, pancreas, gastrointestinal tract, and other tissues. Release can constrain secretion and excitability within local networks as well as endocrine axes. The same peptide can participate in different feedback circuits depending on cell source and receptor distribution. A systemic concentration does not reveal the direction or magnitude of every local somatostatin signal.
Five receptor subtypes diversify the response
SSTR1 through SSTR5 are GPCRs with overlapping but distinct tissue distribution, coupling, trafficking, and ligand pharmacology. They commonly engage inhibitory G proteins, reducing cyclic AMP while also affecting ion channels and kinase pathways. Receptor heterogeneity means a cell-line response at one subtype cannot stand in for the integrated organism system. Desensitization and internalization add time dependence.
Native peptides and stable analogues are separate entities
Engineered somatostatin analogues can change sequence, receptor preference, stability, and exposure. Evidence from those compounds should not be presented as if it describes endogenous somatostatin-14 or -28 directly. This page focuses on the native biological system and makes no claim about treatment, administration, or individual use.
Records should specify endogenous peptide, analogue, receptor subtype, and assay time course. A sustained response to a stable analogue can differ from brief native secretion even when both engage part of the same receptor family.
Evidence limits
- Assays may differ in recognition of somatostatin-14, somatostatin-28, precursors, and fragments.
- Receptor subtype findings vary across tissues, species, models, and time scales.
- No analogue, treatment, administration, or personal use is evaluated.
Sources and further reading
These sources ground the definitions and evidence boundaries on this page. A citation is a route for verification, not an endorsement of a product or personal use.
UniProt Consortium
SST - Somatostatin - Homo sapiens
Reviewed human precursor entry with mature chains, disulfide, sequence, functions, and references.
Open sourceNational Center for Biotechnology Information
SST Somatostatin Gene
Official human gene record linking RefSeq products, genomic context, expression, and research references.
Open sourceCommon questions
Are somatostatin-14 and somatostatin-28 encoded by different genes?
No. Both are processed from preprosomatostatin encoded by SST.
How many somatostatin receptor subtypes are recognized?
Five GPCR subtypes, SSTR1 through SSTR5, with overlapping but distinct biology.
Are stable somatostatin analogues identical to native somatostatin?
No. They can differ in sequence, receptor preference, stability, and exposure.
Continue with context
Continue in the evidence workspace
Explore the complete PeptideSchool research workspace to organize sources, compare evidence layers, and follow related peptide science. Premium tools remain educational and do not provide individualized medical guidance.